en · de · es · fr · pt
ipamorelin-notes.peptides1004.com › Guide › Ipamorelin Background And Pharmacology — Practical Notes

Ipamorelin Background And Pharmacology — Practical Notes

By Editorial Desk · published 2026-01-08 · last reviewed 2026-02-08 · Guide

This is a working overview of ESI-MS, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-02-08. Anything still debated is marked as such rather than presented as settled.

Ipamorelin Background and Pharmacology

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Analytical Methods and Storage Stability

Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.

Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.

Ipamorelin at a glance

PropertyValueNotes
Chemical classSynthetic pentapeptideGrowth hormone secretagogue family
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2Contains two non-natural residues
Molecular formulaC38H49N9O5Free base form
Molecular weight711.85 g/molCalculated from formula
Primary targetGHS-R1a ghrelin receptorAgonist activity

Handling Storage And Analytical Control

In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.

Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.

Related pages on this site

背景与受体作用机制

现有文献多来自小规模、短期的研究,涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏,以及重复给药后效应是否衰减,仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大,因此结论外推需谨慎。关于临床获益的确切证据尚不充分,需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Reference notes

=== Gene therapy === Gene therapy for hemoglobinopathies was first trialled in 2014 on a single patient with sickle cell disease (a fault in the beta globin gene), and followed by clinical trials in which a number of patients with either sickle cell or beta thalassemia were successfully treated. Gene therapies work by first harvesting the patient's HSCs, then using CRISPR gene editing to modify their DNA in the laboratory. In parallel with this, the person with thalassemia disease undergoes a myeloablation procedure (a form of chemotherapy) to destroy the remaining HSCs in their bone marrow. The laboratory treated cells are then infused back into the patient where they colonise the bone marrow and eventually commence production of healthy blood cells. There are fewer risks from this procedure than from HSCT, since the transplanted cells are autologous having originated from the patient herself/himself. There are two approved forms of gene therapy for beta thalassemia. Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia which adds a healthy beta-globin gene to the HSCs. It was approved for medical use in the United States in August 2022. The procedure involves collecting hematopoietic stem cells (HSCs) from the affected person's blood. In the laboratory, these HSCs then have a new gene for T87Q-globin (a modified beta-globin) introduced to them using a lentiviral vector.

== Total synthesis == Due to the high potency and clinical need for cancer treatments, epothilones have been the target of many total syntheses. The first group to publish the total synthesis of epothilones was S. J. Danishefsky et al. in 1996. This total synthesis of epothilone A was achieved via an intramolecular ester enolate-aldehyde condensation. Other syntheses of epothilones have been published by Nicolaou, Schinzer, Mulzer, and Carreira. In this approach, key building blocks aldehyde, glycidols, and ketoacid were constructed and coupled to the olefin metathesis precursor via an aldol reaction and then an esterification coupling. Grubbs' catalyst was employed to close the bis terminal olefin of the precursor compound. The resulting compounds were cis- and trans-macrocyclic isomers with distinct stereocenters. Epoxidation of cis- and trans-olefins yield epothilone A and its analogs. One of the total syntheses of epothilone B is outlined below and was described by the laboratory of K. C. Nicolaou. The retrosynthetic analysis revealed 1, 2, and 3 as the building blocks (Figure 1).

The inhibition of PFK1 by ATP is unusual since ATP is also a substrate in the reaction catalyzed by PFK1. The active form of PFK1 enzyme is a tetramer that exists in two conformations, only one of which binds the second substrate fructose-6-phosphate (F6P). The PFK1 enzyme has two binding sites for ATP – the active site is accessible in either protein conformation, but ATP binding to the inhibitor site stabilizes the conformation that binds F6P poorly. A number of other small molecules can compensate for the ATP-induced shift in equilibrium conformation and reactivate PFK1, including cyclic AMP, ammonium ions, inorganic phosphate, fructose 1,6-bisphosphate and fructose 2,6-bisphosphate.

On 11 December 1944, the unit was again renamed, becoming 309 Dywizjon Myśliwski "Ziemi Czerwieńskiej" or 309 "Land of Czerwien" Polish Fighter Squadron. In 1945, 303 "Kościuszko" Sqn received 20 Mustangs Mk IV/Mk IVA replacements. Postwar, between 6 December 1946 and 6 January 1947, all five Polish squadrons equipped with Mustangs were disbanded. Poland returned about 80 Mustang Mk IIIs and 20 Mustangs Mk IV/IVAs to the RAF, which transferred them to the US government. Somalia The Somali Air Force operated eight P-51Ds in post-World War II service. South Africa

Sources: en.wikipedia.org

Notes from published material

== History == The mdx mouse was first described in 1984 by Bulfield et al. in a colony of C57BL/10ScSn mice, showing elevated muscle creatine kinase (CK) and histological lesions characteristic of muscular dystrophy. In 1989, Sicinski et al. identified the precise mutation: a C-to-T transition (nonsense point mutation) in exon 23 of the Dmd gene, creating a premature stop codon and abolishing full-length dystrophin expression. This makes mdx mice a key model for Duchenne muscular dystrophy.

== Sponsors == LLNL's principal sponsor is the Department of Energy/National Nuclear Security Administration (DOE/NNSA) Office of Defense Programs, which supports its stockpile stewardship and advanced scientific computing programs. Funding to support LLNL's global security and homeland security work comes from the DOE/NNSA Office of Defense Nuclear Nonproliferation, as well as the Department of Homeland Security. LLNL also receives funding from DOE's Office of Science, Office of Civilian Radioactive Waste Management, and Office of Nuclear Energy. In addition, LLNL conducts work-for-others research and development for various Defense Department sponsors, other federal agencies, including NASA, Nuclear Regulatory Commission (NRC), National Institutes of Health, and Environmental Protection Agency, a number of California State agencies, and private industry.

Lectin affinity chromatography is a form of affinity chromatography where lectins are used to separate components within the sample. Lectins, such as concanavalin A are proteins which can bind specific alpha-D-mannose and alpha-D-glucose carbohydrate molecules. Some common carbohydrate molecules that is used in lectin affinity chromatography are Con A-Sepharose and WGA-agarose. Another example of a lectin is wheat germ agglutinin which binds D-N-acetyl-glucosamine. The most common application is to separate glycoproteins from non-glycosylated proteins, or one glycoform from another glycoform. Although there are various ways to perform lectin affinity chromatography, the goal is extract a sugar ligand of the desired protein.

In February of 2025 the first case of CRISPR gene editing therapy on a child was documented. It was used to treat Severe Carbamoyl Phosphate Synthetase 1 Deficiency. It was administered At Children's Hospital of Philadelphia and is currently successful in its use to counteract the disease. "Advanced Gene Editing: CRISPR-Cas9" (PDF). Congressional Research Service. Archived from the original (PDF) on 5 December 2017. Retrieved 24 October 2017. "Jennifer Doudna talk: Genome Engineering with CRISPR-Cas9: Birth of a Breakthrough Technology". 10 September 2022. Archived from the original on 25 November 2016. Retrieved 24 November 2016. "Human Nature". NOVA. Season 47. Episode 9. 9 September 2020. PBS. WGBH. Retrieved 7 April 2023.

=== Radionuclide === As 241Am has a half-life roughly similar to 238Pu (432.2 years vs. 87 years), it has been proposed as an active element of radioisotope thermoelectric generators, for example in spacecraft. Although americium produces less heat and electricity – the power yield is 114.7 mW/g for 241Am and 6.31 mW/g for 243Am (cf. 390 mW/g for 238Pu) – and its radiation poses more threat to humans owing to neutron emission, the European Space Agency is considering using americium for its space probes. Another proposed space-related application of americium is a fuel for space ships with nuclear propulsion. It relies on the very high rate of nuclear fission of 242mAm, which can be maintained even in a micrometer-thick foil. Small thickness avoids the problem of self-absorption of emitted radiation. This problem is pertinent to uranium or plutonium rods, in which only surface layers provide alpha-particles. The fission products of 242mAm can either directly propel the spaceship or they can heat a thrusting gas. They can also transfer their energy to a fluid and generate electricity through a magnetohydrodynamic generator. One proposal which utilizes the high nuclear fission rate of 242mAm is a nuclear battery. Its design relies not on the energy emitted by americium alpha particles but on their charge. In this way the americium acts as a self-sustaining cathode. A single 3.2 kg 242mAm charge of such a battery could provide about 140 kW of power over a period of 80 days.

Sources: en.wikipedia.org

Further detail

Rosiglitazone is a member of the thiazolidinedione class of drugs. Thiazolidinediones act as insulin sensitizers. They reduce glucose, fatty acid, and insulin blood concentrations. They work by binding to the peroxisome proliferator-activated receptors (PPARs). PPARs are transcription factors that reside in the nucleus and become activated by ligands such as thiazolidinediones. Thiazolidinediones enter the cell, bind to the nuclear receptors, and alter the expression of genes. The several PPARs include PPARα, PPARβ/δ, and PPARγ. Thiazolidinediones bind to PPARγ. PPARs are expressed in fat cells, cells of the liver, muscle, heart, and inner wall (endothelium) and smooth muscle of blood vessels. PPARγ is expressed mainly in fat tissue, where it regulates genes involved in fat cell (adipocyte) differentiation, fatty acid uptake and storage, and glucose uptake. It is also found in pancreatic beta cells, vascular endothelium, and macrophages Rosiglitazone is a selective ligand of PPARγ and has no PPARα-binding action. Other drugs bind to PPARα. Rosiglitazone also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Nuclear factor kappa-B (NF-κB), a signaling molecule, stimulates the inflammatory pathways. NF-κB inhibitor (IκB) downregulates the inflammatory pathways. When patients take rosiglitazone, NF-κB levels fall and IκB levels increase.

The possibility is mentioned, above, that all living organisms may be descended from an original single-celled organism with a DNA genome, and that this implies a single origin for life. Although such a universal common ancestor may have existed, such a complex entity is unlikely to have arisen spontaneously from non-life and thus a cell with a DNA genome cannot reasonably be regarded as the origin of life. To understand the origin of life, it has been proposed that DNA based cellular life descended from relatively simple pre-cellular self-replicating RNA molecules able to undergo natural selection. During the course of evolution, this RNA world was replaced by the evolutionary emergence of the DNA world. A world of independently self-replicating RNA genomes apparently no longer exists (RNA viruses are dependent on host cells with DNA genomes). Because the RNA world is apparently gone, it is not clear how scientific evidence could be brought to bear on the question of whether there was a single origin of life event from which all life descended.

Beginning in the 2000s, many countries introduced e-visas and electronic travel authorisations (ETAs) as an alternative to traditional visas. An ETA is a form of pre-arrival registration, which may or may not be officially classified as a visa depending on the issuing jurisdiction, and is required for foreign travellers who are exempt from obtaining a full visa. In contrast to the procedures that typically apply regarding proper visas, under which the traveller normally has no recourse if rejected, if an ETA is rejected, the traveller can choose to apply for a visa instead. In contrast, an e-visa is a visa that travellers can apply for and obtain online, without visiting the issuing state's consular mission or visa agency. The following jurisdictions require certain categories of international travellers to hold an ETA or e-visa to clear border controls upon arrival:

=== Robert Spearing Sr. === Robert Spearing Sr. (Rick Warden) is Robert's working-class father, who works as a bartender. Robert Sr. was largely absent throughout his son's upbringing, which he left to Robert's domineering mother who died prior to the events of the series. Robert Sr. since remarried and had two children with his new wife, while remaining estranged from Robert. Robert visits his father in series 2, and breaks his sobriety after an argument with him. Robert Sr. finds his son drunk and passed out outside his apartment, and lets him stay the night; the two reconcile the morning after, with Robert Sr. assuring his son he has nothing to apologize for.

After the break-up of the Soviet Union in 1991, bromantane continued to be researched and characterized but was mainly limited in use to sports medicine (for instance, to enhance athletic performance). In 1996, it was encountered as a doping agent in the 1996 Summer Olympics when several Russian athletes tested positive for it, and was subsequently placed on the World Anti-Doping Agency banned list in 1997 as a stimulant and masking agent. Bromantane was eventually repurposed in 2005 as a treatment for neurasthenia. It demonstrated effectiveness and safety for the treatment of the condition in extensive, large-scale clinical trials, and was approved for this indication in Russia under the brand name Ladasten sometime around 2009.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.

Which receptor does ipamorelin act on?

It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.

How does it differ from other secretagogues?

Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.

How is ipamorelin purity normally measured?

The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.

Network